[HTML][HTML] Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population
CB Westphalen, MG Krebs, C Le Tourneau… - NPJ precision …, 2021 - nature.com
Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions are rare oncogenic drivers
in solid tumours. This study aimed to interrogate a large real-world database of …
in solid tumours. This study aimed to interrogate a large real-world database of …
Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities
L Chang, NY Jung, A Atari, DJ Rodriguez, D Kesar… - Nature Genetics, 2023 - nature.com
The paradigm of cancer-targeted therapies has focused largely on inhibition of critical
pathways in cancer. Conversely, conditional activation of signaling pathways as a new …
pathways in cancer. Conversely, conditional activation of signaling pathways as a new …
[HTML][HTML] Prevalence and mutational determinants of high tumor mutation burden in breast cancer
Background High tumor mutation burden (TMB) can benefit immunotherapy for multiple
tumor types, but the prevalence of hypermutated breast cancer is not well described. The …
tumor types, but the prevalence of hypermutated breast cancer is not well described. The …
Mutational processes shape the landscape of TP53 mutations in human cancer
AO Giacomelli, X Yang, RE Lintner, JM McFarland… - Nature …, 2018 - nature.com
Unlike most tumor suppressor genes, the most common genetic alterations in tumor protein
p53 (TP53) are missense mutations,. Mutant p53 protein is often abundantly expressed in …
p53 (TP53) are missense mutations,. Mutant p53 protein is often abundantly expressed in …
[HTML][HTML] The evolving landscape of biomarker testing for non-small cell lung cancer in Europe
KM Kerr, F Bibeau, E Thunnissen, J Botling, A Ryška… - Lung Cancer, 2021 - Elsevier
The discovery of oncogenic driver mutations rendering non-small cell lung cancer (NSCLC)
targetable by small-molecule inhibitors, and the development of immunotherapies, have …
targetable by small-molecule inhibitors, and the development of immunotherapies, have …
Rare molecular subtypes of lung cancer
Oncogenes that occur in≤ 5% of non-small-cell lung cancers have been defined as 'rare';
nonetheless, this frequency can correspond to a substantial number of patients diagnosed …
nonetheless, this frequency can correspond to a substantial number of patients diagnosed …
The emerging clinical relevance of genomics in cancer medicine
The combination of next-generation sequencing and advanced computational data analysis
approaches has revolutionized our understanding of the genomic underpinnings of cancer …
approaches has revolutionized our understanding of the genomic underpinnings of cancer …
Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers
N Pozdeyev, LM Gay, ES Sokol, R Hartmaier… - Clinical Cancer …, 2018 - AACR
Purpose: To define the genetic landscape of advanced differentiated and anaplastic thyroid
cancer (ATC) and identify genetic alterations of potential diagnostic, prognostic, and …
cancer (ATC) and identify genetic alterations of potential diagnostic, prognostic, and …
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
Abstract The RAS–RAF–MEK–ERK signaling cascade is among the most frequently mutated
pathways in human cancer. Approximately 50% of melanoma patients possess a druggable …
pathways in human cancer. Approximately 50% of melanoma patients possess a druggable …
[HTML][HTML] Genomic mapping of metastatic organotropism in lung adenocarcinoma
Summary We analyzed 2,532 lung adenocarcinomas (LUAD) to identify the
clinicopathological and genomic features associated with metastasis, metastatic burden …
clinicopathological and genomic features associated with metastasis, metastatic burden …